Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Genentech, Idec deal

GNE will provide $9 million upfront in preferred equity and licensing fees, $17.5 million in additional equity funding prior to U.S. approval, and up to $30.5 million

Read the full 279 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE